post-add

Articles for Finance

Drug Exports Jumped 29% In October, To Touch USD 28 Bn In FY24: Pharmexcil

From April to October, India’s drug exports grew by 8 per cent year on year to USD 15.7 billion versus USD 14.5 billion in the same period last year. “In October, the exports jumped by 29 per cent against 5 per cent growth all along this year and due to this momentum, we are projecting that pharmaceutical exports can clock 28 billion USD in FY24,” the Chairman said

Read More
Eli Lilly Extends Deadline For Point Biopharma Share Sale Amid Participation Concerns

Reportedly, the extension comes after Lilly's October agreement to acquire Point Biopharma in an all-cash deal valued at USD 1.4 billion, aimed at gaining access to the innovative therapies developed by Point Biopharma for precise cancer targeting

Read More
Fortis Healthcare Posts Strong Q2 Results, Targets 20% EBITDA Margin By FY24-25

The company has reiterated its margin guidance, targeting a 20 per cent EBITDA margin by Q4FY24 or Q1FY25, coupled with an occupancy goal of 70 per cent

Read More
HealthCare Global Enterprises (HCG) Records Robust Q2 EBITDA Growth, Aims For 20 per cent Margin By FY24-25

New centres reported a substantial EBITDA growth of 21 per cent year-on-year (23 per cent quarter-on-quarter) to Rs. 122 million

Read More
Apollo Hospitals' Q2 EBITDA Soars To Rs. 6.3 Billion, Propelling Rs. 34 Billion Expansion Plan For FY25

The latest financial report reveals that APHS reported consolidated Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of Rs 6.3 billion, marking a significant 23 per cent quarter-on-quarter increase

Read More
Dr Reddy’s Ventures into Renewable Energy with O2 Power SPV Acquisition

Dr Reddy invested Rs 42.78 lakh, equivalent to 26 per cent of the equity share capital, and an additional Rs 72.84 lakh in compulsorily convertible debentures

Read More
Glenmark Pharmaceuticals Reports Strong Q2 FY 2023-24 Growth With 6.3% YoY

The operating EBITDA stood at Rs. 6,732 Mn, indicating an impressive 8.3 per cent increase, with margins reaching 18.8 per cent

Read More
Fortis Healthcare Reports Strong Q2 FY24 Financials, Agilus Diagnostics Files IPO

Fortis Healthcare showcased an improvement in net debt to EBITDA, standing at 0.29 compared to 0.44 annually for Q2 FY24 and Q2 FY23

Read More

Subscribe to our newsletter to get updates on our latest news